Actively Recruiting
RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
Led by University of Alabama at Birmingham · Updated on 2025-10-31
40
Participants Needed
1
Research Sites
484 weeks
Total Duration
On this page
Sponsors
U
University of Alabama at Birmingham
Lead Sponsor
V
Varian Medical Systems
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study offers 5 fractions of radiation treatment through partial breast irradiation in patients with early stage breast cancer after having a lumpectomy.
CONDITIONS
Official Title
RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically proven invasive mammary carcinoma, invasive ductal carcinoma (IDC), or ductal carcinoma in situ (DCIS) of the breast, including medullary, papillary, mucinous (colloid), and tubular histologies
- Age over 50 years
- Maximum tumor size less than 2.0 cm if invasive carcinoma or less than 2.5 cm if pure DCIS
- Estrogen receptor (ER) positive with more than 10% expression
- Eligible for breast conservation therapy and have received a lumpectomy with pathologic margins of at least 2 mm
- Clinically node negative by physical examination; sentinel node dissection not required but if done, must be pathologically node negative
- Zubrod Performance Status of 0 to 2
You will not qualify if you...
- Multifocal or multicentric cancer
- Previous neoadjuvant chemotherapy
- Pure invasive lobular histology
- Inability to clearly see the lumpectomy cavity on post-lumpectomy planning scan
- Planning target volume (PTV) greater than 124 cc
- Lumpectomy cavity located within 5 mm of the body contour
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC)
Birmingham, Alabama, United States, 35233
Actively Recruiting
Research Team
D
D. Hunter Boggs, MD
CONTACT
D
D. Hunter Boggs, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here